Tandem Diabetes Care, Inc. (TNDM)
Tandem Diabetes Care, Inc. is a medical device company that develops and commercializes products for the management of insulin-dependent diabetes. Founded in 2008 and headquartered in California, the company is known for its innovative insulin pump systems, including the t:slim X2 insulin pump, designed to improve diabetes treatment through advanced technology and user-friendly features. Tandem aims to empower people with diabetes to achieve better health outcomes through integrated and automated insulin delivery solutions.
Company News
Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care shareholders after the company issued a voluntary medical device correction for select t:slim X2 insulin pumps, causing a 19.9% stock price drop.
The Schall Law Firm is investigating potential securities law violations by Tandem Diabetes Care after the company disclosed a critical insulin pump malfunction that could interrupt insulin delivery and potentially harm patients.
Tandem Diabetes Care received approval from the European Union's European Medicines Agency to use its t:slim X2 automated insulin delivery pump with Eli Lilly's Lyumjev ultra-rapid acting insulin. This is a positive development for both companies as they plan to expand the compatibility to other markets.
Boston Scientific Corporation is scheduled to report its Q2 2024 results on July 24. The company is expected to report revenue growth of around 11.7% and adjusted earnings of 58 cents per share. However, the company may face challenges from a challenging supply environment, rising costs, and healthcare staffing shortages.
Abbott Laboratories on Wednesday reported fourth-quarter sales that topped expectations amid strength in its medical-device and nutrition segments.